+

WO1992022657A1 - Expression et systeme de detection de conjugues antigene-enzyme - Google Patents

Expression et systeme de detection de conjugues antigene-enzyme Download PDF

Info

Publication number
WO1992022657A1
WO1992022657A1 PCT/US1992/004866 US9204866W WO9222657A1 WO 1992022657 A1 WO1992022657 A1 WO 1992022657A1 US 9204866 W US9204866 W US 9204866W WO 9222657 A1 WO9222657 A1 WO 9222657A1
Authority
WO
WIPO (PCT)
Prior art keywords
vector
gene
dna
cloning vector
protein
Prior art date
Application number
PCT/US1992/004866
Other languages
English (en)
Inventor
Lawrence A. Dreyfus
Robert G. Urban
Original Assignee
Board Of Regents, The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Regents, The University Of Texas System filed Critical Board Of Regents, The University Of Texas System
Publication of WO1992022657A1 publication Critical patent/WO1992022657A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • the invention relates generally to recombinant expression vectors useful for host cell expression of readily identifiable fusion proteins. These vectors are useful in a wide range of applications, e .g. , in rapid and convenient techniques for the preparation of antigenic fusion proteins or peptides, and for isolating specific gene sequences which encode these products.
  • Protein export from bacterial host cells using recombinant expression vectors has been explored as a method of synthesizing relatively large quantities of biologically active polypeptides.
  • Methods typically utilize expression vectors which have been introduced into a suitable host bacterial cell, such as Escherichia coli .
  • a suitable host bacterial cell such as Escherichia coli .
  • toxic effects on the host, expression of undesired protein products and production of nonfunctional proteins are some of the problems encountered with the use of expression vectors.
  • Special expression vectors have been developed for production of proteins such as human growth factor (Yano and Muri, 1990) .
  • most expression vectors are limited in the range of DNA segments that may be accepted.
  • Plasmid vectors have been constructed for transforming E. coll host cells in which portions of genes specifying both periplasmic and outer membrane proteins were fused to modified alkaline phosphatase
  • prokaryotic vectors capable of producing alkaline phosphatase fused hybrid polypetides have been described.
  • Piatak et al . (1990) vector an active ricin A protein was produced in a prokaryotic host by linking the ricin A coding sequence with a terminated leader DNA sequence from alkaline phosphatase (Piatak, et al . , 1990).
  • the desired protein coding sequence was out of reading frame with the leader sequence and provided a ricin A gene product only when properly fused.
  • the protein was produced intracellularly, a fused alkaline phosphatase product was not obtained, and the protein was not secreted.
  • European patent 0352839 (Yano and Mural, 1990) describes construction of a plasmid that was used to express hEGF (human epidermal growth factor) from an E. coli host cell. Like other specific use plasmids, this vector had a promoter, . the desired gene (cloned DNA) and an alkaline phosphatase signal peptide gene. The expressed product was not fused with alkaline phosphatase, so detection and isolation depended on standard protein product isolation separation from the medium.
  • hEGF human epidermal growth factor
  • Gene fusions are utilized for a number of purposes, including studies on protein secretion and folding (Smith et al . , 1987), methods of simplifying protein purifications (Piatak et al . , 1990), and development of specific immunogens (Chondra, 1990) .
  • One popular use of gene fusion products is the production of bifunctional hybrid proteins which are useful in enzyme immunoassays (EIA) as "capture” agents.
  • EIA enzyme immunoassays
  • an antibody is coupled with another protein that is readily detectable. The antibody then binds to specific antigens and is quantitated by virtue of the coupled "reporter” protein.
  • Bifunctional hybrid proteins have included, in addition to antibodies.
  • Protein A, Protein G and streptavidin conjugated to reporter proteins such as alkaline phosphatase or horseradish peroxidase.
  • reporter proteins such as alkaline phosphatase or horseradish peroxidase.
  • Preparation of these reagents involves purification of each protein followed by covalent coupling and purification of.the fusion product. Such processes are time-consuming, expensive and necessarily limit the number of hybrids that can be screened.
  • the present invention addresses one or more of the foregoing or other problems by providing a general recombinant vector design that allows overexpression and secretion of a recombinant fusion protein, accepts DNA from a wide variety of sources, and utilizes reading frame restoration between two otherwise silent genetic elements.
  • the invention will generally allow the rapid identification of successful gene fusions after random insertion of a desired DNA without need to screen a large number of independent clones.
  • the cloning vector of the present invention is designed to allow the expression of a fusion protein from a host cell.
  • the most general structure of the cloning vector includes, in order, an inducible promoter sequence, a multiple cloning site, and a reporter gene.
  • the reporter gene product is capable of being exported into host cell periplas ic space and is also capable of expression as a fusion product with a protein product of DNA inserted into the multiple cloning site with a proper reading frame.
  • the inducible promoter sequence is upstream of the other DNA segments.
  • the cloning vector does not express a gene product until a foreign DNA is inserted into the multiple cloning site with a correct reading frame.
  • the resulting fusion product is a bipartite hybrid protein composed of a reporter protein and the gene product encoded by the inserted DNA.
  • This cloning vector is useful for expression of fusion proteins derived from DNA having segments encoding signal peptide or equivalent function. Generally this is eukaryotic DNA but could be other DNA with a signal peptide element.
  • the incorporation of a signal peptide coding sequence in the cloning vector with an inducible promoter sequence, multiple cloning site and reporter gene sequence allows expression of a wide range of DNAs, including eukaryotic DNA that may lack a signal sequence segment as well as prokaryotic DNA.
  • the signal peptide sequence is located downstream of the inducible promoter sequence and is not expressed until the DNA encoding a target or desired protein is positioned within the multiple cloning site. This positioning allows a translational reading to be established so that a protein fusion product- is expressed with the reporter gene product. Neither the signal peptide nor the reporter gene product will be expressed individually. Thus those gene segments are silent until a DNA inserts into the multiple cloning site to connect the signal and reporter gene segments.
  • the cloning vector optionally includes a "tag" gene positioned between the signal peptide coding sequence and the multiple cloning site.
  • tag is meant a gene coding for a polypeptide that when expressed as a fusion polypeptide will elicit an antigenic response when challenged with antibodies directed to its gene product.
  • the product of this tag gene is thus an antigenic peptide attached to the amino terminus of the fusion product of the reporter gene and inserted DNA. The presence of the tag therefore provides an easy means of separation or detection with antibodies specific for the protein product of the tag gene.
  • the amino-ter inal tags are typically fairly short, for example, a thirteen amino acid sequence such as Ser-Thr-Gln-Ser-Asn-Lys-Lys-Asp- Pro-Leu-Glu-Ser-Thr.
  • longer sequences of antigenic polypeptide tags may be used, the shorter ones are preferred as this will decrease the amount of reading required in order to express the gene product. Longer gene sequences frequently exhibit lower production rates because mRNA reading efficiency decreases with length of reading frame.
  • the inducible promoter sequence used typically does not include a translation initiation site but includes only a bacteriophage transcription element.
  • the promoter transcription element is typically from bacteriophage T7 but could be from other bacteriophage including T3, SP6 or ⁇ .
  • a preferred bacteriophage promoter transcription element is found in T7 bacteriophage and has the base sequence TTAATACGACTCACTAT.
  • a preferred signal peptide gene is a segment from the estB gene.
  • the signal peptide encoded by this gene has the following amino acid sequence: Met-Lys-Lys-Asn- Ile-Ala-Phe-Leu-Leu-Ala-Ser-Met-Phe-Val-Phe-Ser-Ile-Ala- Thr-Asn-Ala-Tyr-Ala. Minor changes in amino acid sequence arising from modification of the base sequence of the gene could be made without impairing the function of this signal peptide.
  • the signal peptide allows a newly synthesized protein to be transported through the inner membrane during which time the signal peptide is cleaved from the amino-terminus of the polypeptide. Protein secretion requires a signal peptide; otherwise, proteins remain in the cytoplasmic compartment.
  • a reporter gene is located downstream of the multiple cloning site.
  • the reporter gene product forms a fusion protein with the gene product of the inserted DNA.
  • the reporter gene may encode a phosphatase, a peroxidase, luciferase, or ⁇ -lactamase.
  • the reporter gene is the phoA gene of E. coli encoding alkaline phosphatase.
  • the reporter gene will preferentially encode a protein or peptide capable of being exported; otherwise, protein fusions produced ay remain in the host cell cytoplasm. Unless exported to the periplasm, fusion proteins are generally not accessible for easy detection and are subject to proteolysis by cytoplasmic proteases. Exported polypeptide gene fusion products are detectable by methods suited to the particular product of the reporter gene, for example, colorimetric, fluorescence or enzymatic analysis.
  • the multiple cloning site within the cloning vector is not limited to any particular base sequence. While there are no limitations on length, it is preferable to limit the multiple cloning site length so that its incorporation as part of the gene fusion will not add unduly to the length of the resulting fusion protein. Of course the entire cloning site is not always incorporated, depending on which site is utilized for introduction of target DNA into the vector. Regardless of its length or composition, the multiple cloning site should be devoid of translational stop codons in all three reading frames to insure that all possible reading frames of target DNA can be used. Thus one or more restriction sites may be incorporated into the sequence.
  • cleavage sites for endonucleases Xbal, Sail, and Pstl are present.
  • a typical multiple cloning site without stop codons and possessing cleavage sites for these restriction endonucleases may have the base sequence AGATCCTCTAGAGTCGACCTGCAGC.
  • cleavage sites recognized by restriction endonucleases - ⁇ nal, Smal, BaiziHI, Sail and Pstl are present. Other restriction sites may be utilized, however, depending on the composition of the multiple cloning site.
  • the cloning vector optionally includes a gene that allows identification of host cells transfected with the cloning vector. In preferred embodiments this will be a gene conferring antibiotic resistance on the transfected cell. This gene segment is typically located in another site on the vector and will be expressed independently of gene fusion products. There are several genes that could be used for conferring antibiotic resistance. In a preferred embodiment, the bla gene encoding ⁇ -lactamase and encoding antibiotic resistance is incorporated into the cloning vector. This gene confers an ampicillin resistance on the host microorganism.
  • DNA termini resulting from endonuclease cleavage are modified to accept DNA. This is preferably accomplished using DNA polymerase I Klenow fragment.
  • the DNA intended for insertion is made blunt-ended by treating with the Klenow fragment and a mixture of the four deoxy nucleotide triphosphates. Not all fragments will be restored to the proper reading frame by this procedure.
  • the target DNA is preferably digested partially with a frequent-cutting restriction endonuclease such as one recognizing a 4 base-pair sequence and the overhang sequentially filled in four separate reactions with one base at a time. Treatment with mung bean or S, nuclease then cleaves the remaining single-stranded overhang. This will effectively restore every possible reading frame of the target DNA segment.
  • primary gene fusion constructs may be prepared from many different sources of DNA including viral, eukaryotic, prokaryotic, or even synthetic DNAs.
  • primary gene fusion constructs refer to the plasmid vectors containing inserted target DNA fused in the same translational frame with a signal peptide and/or reporter gene segment(s) .
  • Genomic DNA if fragmented so that stop codons are removed, can also be inserted into the multiple cloning site and a gene fusion product expressed.
  • the presence of stop codons does not necessarily preclude translation of desired fused genes, provided stop codons fail to effectively terminate translation.
  • any transcribable and translatable DNA segments may be inserted into the multiple cloning site of the vectors of the invention, for example suitable DNA segments prepared by shearing or fragmenting the DNA of interest.
  • fusion proteins from eukaryotic DNA will not be effectively expressed from a cloning vector unless a signal peptide coding sequence is incorporated into the vector.
  • a vector will also include a ribosomal binding (Shine-Dalgano) site, which is a short segment adjacent to the inducible promoter sequence.
  • a preferred Shine-Dalgano sequence is 5'-GGAGGA-3'. Ribosomal binding sites allow ribosomes to load onto mRNA and initiate translation.
  • cloning vectors may be produced by the aforementioned methods of vector construction.
  • One particular embodiment for example, is a cloning vector encoding T7 transcriptional promoter, Shine-Dalgano translational promoter, a prokaryotic secretory signal peptide and an im unoaffinity tag.
  • p-ANTIGEN-2 is a particular example constructed with the ⁇ lO promoter, an ampicillin resistance gene and an immunoaffinity tag with the particular base sequences shown in Figure 1.
  • This expression vector is useful for accepting prokaryotic DNA, for example, influenza viral DNA segments or HIV-1 DNA segments.
  • p-ANTIGEN-3 This example of an expression plasmid may be used to express eukaryotic DNA. Its base sequence is shown in Figure 2 and unlike p-ANTIGEN-2 embodiments, lacks a signal peptide sequence. This embodiment includes the ⁇ io promoter and a leaderless and promoterless bacterial alkaline phosphatase gene.
  • the invention concerns a method for detecting antigenic proteins or peptides.
  • the method includes first preparing one of the above- described cloning vectors, inserting DNA segment(s) into the multiple cloning site of such vector, and transforming it into a host cell.
  • Vector-containing host cells are selected and expression of protein fusion constructs induced. Colonies which produce an antigenic protein or peptide fused with the expression product of the reporter gene are then identified.
  • the cloning vector may be designed to accept either eukaryotic or prokaryotic DNA depending on whether a signal peptide sequence is included.
  • the invention also contemplates that antibodies specific for a desired antigenic protein or peptide may be obtained from animal or human serum. This is accomplished by exposing the animal to a disease-causing agent, by injecting with a selected vaccine and allowing antibodies to develop or the like. Antibodies may then be isolated from the serum and used in antigen capture methods with the antibodies fixed to a matrix. Exemplary matrices include plastic microtiter plates, nitrocellulose filters or other accepted immobilization surfaces.
  • primary gene fusions may be modified so that polypeptides are produced without a fusion partner, that is, without the reporter gene.
  • a fusion partner refers to one of the proteins encoded by two genes in a cloning vector where a single protein product is expressed.
  • the partner refers to the protein used as the reporter protein and is permanently incorporated into the originally designed vector.
  • the steps involve digesting the primary gene fusion construct in the cloning vector with a restriction endonuclease to remove the reporter gene segment.
  • the digested gene fusion construct is then treated with DNA ligase to reseal the cloning vector.
  • the resultant cloning vector may be transformed into a suitable whole cell such as one containing an inducible T7 RNA polymerase gene.
  • the desired polypeptide then may be expressed without the fusion partner. This method is particularly useful for obtaining polypeptide gene products desirable as antigens or vaccine candidates.
  • the host cell used in this method is typically E. coll , although other bacterial hosts may be used, such as Salmonella typhimurium, Erwina carotavora, Klebsiella pneumoniae and like microorganisms.
  • kits useful for the expression of fusion proteins are also envisioned comprising separate containers each having suitably aliquoted reagents for performing the foregoing methods.
  • the containers may include one or more vectors prepared in accordance with claim 1, particular examples being pANTIGEN-2 or pANTIGEN-3.
  • Suitable containers might be vials made of plastic or glass, various tubes such as test tubes, metal cylinders, ceramic cups or the like.
  • Containers may be prepared with a wide range of suitable ali uots, depending on applications and on the scale of the preparation. Generally this will be an amount that is conveniently handled so as to minimize handling and subsequent volumetric manipulations.
  • restriction endonucleases such as Kpnl , Smal , BamRI , Xmal , Sail , and Pstl from common supplies usually on hand; however, such restriction endonucleases could also be optionally included in a kit preparation.
  • Vectors supplied in kit form are preferably supplied in lyophilized form, although such DNA fragments may also be taken up in a suitable solvent such as ethanol, glycols or the like and supplied as suspensions. For most applications, it would be desirable to remove solvent which for ethanol, for example, is a relatively simple matter of evaporation.
  • Figure 1 shows a partial DNA and deduced amino acid sequence of pANTIGEN-2.
  • Base sequences 1-15 encode the T7 promoter.
  • a signal peptide is encoded by nucleotides 61-130 and nucleotides 131-152 code for an antigen tag. Part of the alkaline phosphatase gene is shown beginning at base 162.
  • Figure 2 shows a partial DNA and deduced amino acid sequence of pANTIGEN-3.
  • Bases 1-15 encode the T7 promoter.
  • the N-terminal sequence of alkaline phosphatase is shown beginning at base number 39.
  • Figure 3 is a Western blot of HIV-1 env-phoA gene fusion products with a monoclonal antibody to E. coli alkaline phosphatase.
  • Panel A is a Western blot using a monoclonal antibody specific for bacterial alkaline phosphatase.
  • Panel B is an autoradiogram of the same blot shown in Panel A, demonstrating T7 mediated exclusive metabolic radiolabeling.
  • Lane 1 prestained markers
  • lane 2 bacterial alkaline phosphatase
  • lanes 2-7 clones 6, 12, 15, 19, 20 and 29 respectively.
  • Figure 4 is a schematic map of selected HIV-1 gpl20- phoA fusion clones.
  • Figure 5 is a schematic representation of the enzyme immunoconjugate assay.
  • A indicates wells precoated with the immuno-absorbent anti-F c antibody.
  • B shows addition of test antibody, c shows addition of epitope-enzyme conjugate and 4 indicates identification of bound conjugate by cleavage of chromogenic substrate.
  • Figure 6 shows results of an enzyme immuno-conjugate assay on selected gpl20-phoA clones and HIV+ serum samples.
  • Figure 7 shows an N-terminal tag capture of pANTIGEN-2 expressed Env-PhoA fusion proteins.
  • the present invention provides a general design for a cloning vector capable of producing one or more desired proteins fused to a marker protein.
  • the marker or "reporter” protein is encoded by a gene which is part of the vector design, but the protein segment fused to the reporter may derive from any of an enormous array of DNA segments incorporated into the vector.
  • Cloning vectors of the invention are constructed so that a multiple cloning site for target DNA is positioned between a reporter gene and a signal peptide coding segment.
  • the signal coding segment will act as a signal sequence for a DNA that inserts into the cloning site.
  • a wide range of DNA segments inserted with the proper reading frame will be produced as a tripartite fusion protein with the signal peptide fused to the N- terminal end of the target protein which in turn is fused to the N-terminal end of the reporter gene product.
  • the final expressed product will appear in the periplasm of the host cell without the signal peptide which is lost during exportation of the gene fusion product from the cytoplasm.
  • the expressed gene fusion product is readily detected by taking advantage of the properties of the reporter gene product.
  • This product is typically a protein with enzymatic function but could be a protein with other distinct properties such as reactivity toward a fluorophor or antigenic determinants. Detection is most convenient if distinct colonies are visualized, for example, colored colonies on bacteriological media in the presence of a chromogenic indicator that reacts with the product of the reporter gene.
  • PhoA works well as a reporter gene.
  • Its gene product, alkaline phosphatase is expressed when fused with a gene product from the DNA in the cloning site. The alkaline phosphatase is active, once exported into the periplasm of E. coli and is detectable with an indicator that stains blue in the presence of active enzyme.
  • incorporación of a signal peptide coding sequence into the cloning vector contributes to its versatility. Most cloning vectors are limited in the DNA that can be incorporated into the multiple cloning site. If a signal peptide coding sequence is not part of the desired gene DNA sequence inserted into the cloning site, no useful gene fusions will be obtained because exportation will be not possible.
  • By incorporating a signal peptide coding sequence into the vector virtually any length or type of DNA that can be successfully inserted into the site with the correct reading frame will be expressed.
  • the signal peptide encoded by the signal peptide coding sequence enables export of the fusion protein through the cytoplasmic membrane. It is removed during export of the fusion protein into host cell periplasmic space. This increases stability of the expressed protein by avoiding proteases commonly found in the cytoplasm.
  • the multiple cloning site as designed, recognized particular endonucleases, but it will be appreciated that other multiple cloning sites would work as well, provided there are no translational stop codons in any of the possible reading frames.
  • a leaderless, promoterless reporter gene is utilized to prevent expression of the reporter gene in the absence of foreign DNA inserted in the same reading frame as the reporter and/or signal peptide coding segment.
  • the reporter is inactive until exported from the cytoplasm of the host bacterium. Thus only correctly aligned gene fusions give rise to an easily detectable phenotype.
  • alkaline phosphatase is the reporter gene, bacterial colonies expressing alkaline phosphatase turn blue on bacteriological medium containing the alkaline phosphatase chro ogenic substrate 5-bromo-3- indolyl-phosphate.
  • the host cell Since protein fusions are expressed only when the T7 RNA polymerase is induced, the host cell is not subject to inappropriate overproduction, that is, overproduction sufficient to interfere with cell function or continued production of gene fusion products.
  • the alkaline phosphatase reporter gene is highly preferred, other such genes could be incorporated into the vector. Selection should be based on ease of detectability of the gene product, ability to stabilize the target DNA polypeptide product and product activity only when transported out of the cytoplasm. In some cases, it may be desirable to express the target polypeptide without the fusion partner. Thus consideration should be given to restriction endonucleases that may be used to remove the reporter gene from the fusion vector without removing target DNA.
  • the reporter protein is readily removed by cleavage of the fusion construct with Pstl fllowed by resealing the target DNA-containing vector with DNA ligase.
  • This method will work for any target DNA which lacks Pstl sites. Additional strategies based on a similar protocol could be devised based on the target DNA sequence and/or restriction map.
  • the DNA for insertion into the multiple cloning site may be derived from numerous sources, for example, cDNA or genomic DNA, DNA from bacteria, yeast, viruses or higher organisms.
  • cDNA or genomic DNA DNA from bacteria, yeast, viruses or higher organisms.
  • eukaryotic gene sequences with intervening sequences are generally not expressible because the bacterial host cell cannot remove the intervening sequences.
  • the DNA for that product is almost always a cDNA or a synthetic gene.
  • target DNA can be prepared by two different methods, both of which yield target DNA termini which are random with respect to translational reading frame.
  • the first method is to simply shear the DNA by timed sonic disruption precalibrated with respect to DNA concentration and time to yield fragments of the desired length (500-200 base pairs, for example) .
  • DNA treated in this fashion is incubated with DNA polymerase and the four nucleotide triphosphates (dNTPs) to repair any uneven ends.
  • dNTPs nucleotide triphosphates
  • the blunt-ended DNA fragments are then treated with alkaline phosphatase to remove the 5 ' phosphate group from each DNA strand.
  • the vector DNA is prepared by digestion with Sail fllowed by DNA polymerase I and 4dNTPs to fill the restriction enzyme generated overhang. Vector DNA is then ready for mixing and ligation with DNA fragments.
  • a second method for preparing randomly ended DNA fragments is to partially digest the DNA with a restrictiion enzyme such as Sau3A.
  • a restrictiion enzyme such as Sau3A
  • the recognition sequence for Sau3A and the remaining overhang are both GATC.
  • the overhang generated by partial digestion of target DNA can then be sequentially * filled.
  • the remaining DNA is treated with either SI or mung bean nuclease to remove the remaining overhang.
  • the reaction mixtures are then pooled, treated with alkaline phosphatase and combined into the vector.
  • Antigen-enzyme protein fusions generated in a bacterial host may be used for antibody detection. Potential immunogens produced as protein fusions from bacterial host cells do not have to be purified.
  • Transformed host cell colonies with productive fusions may be quickly screened because of the presence of the readily detectable fusion partner.
  • antigen capture with immobilized IgG or IgM polyclonal or monoclonal antibodies allows binding with the appropriate antigen.
  • the fusion partner preferably alkaline phosphatase
  • alkaline phosphatase may then be directly detected by a convenient assay.
  • Traditional methods of antigen detection using labeled antigens prepared from radiolabeled amino acids in the host cell require overnight incubation for autoradiography.
  • a reporter protein colorimetric assay using, for example, alkaline phosphatase can be performed in accordance with the present invention immediately after binding with the capture agent.
  • a leaderless and promoterless bacterial alkaline phosphatase ⁇ phoA gene fragment was removed and purified from the plasmid pCH2 by Pstl restriction enzyme digestion and agarose gel electrophoresis, respectively.
  • the purified phoA fragment was inserted into pUC19
  • p-ANTIGEN-1 has been deposited with the American Type Culture Collection, Accession Number 68501.
  • a DNA fragment encoding a T7 transcriptional promoter, a Shine-Dalgano translational promoter, a prokaryotic secretory signal peptide, and an immunoaffinity purification tag were liberated from the plasmid pUDl by PvuII-BIgTI restriction enzyme digestion.
  • the purified fragment was ligated into Sj ⁇ al-BamHI digested pANTIGEN-1 using T4 DNA ligase to form the plasmid pANTIGEN-2. Correct fragment insertion was verified by restriction analysis using SalX-Nsil, and Xbal-Sa ⁇ l and by DNA sequencing ( Figure 1) .
  • the signal peptide and phoA coding regions were verified by DNA sequence analysis to be in separate reading frames and free of inappropriate stop codons.
  • p-ANTIGEN-2 has been deposited with the American Type Culture Collection under ATCC Accession Number 68502.
  • a DNA fragment encoding a bacteriophage T7 promoter was liberated from the plasmid pT7-5 by PvuII-BaraHI digestion, purified by agarose electrophoresis and ligated into Sinal-Bau-HI digested pANTIGEN-1 using T4 DNA ligase. The resulting plasmid was then linearized by Xbal-Sall digestion, and the overhang was filled by
  • pANTIGEN-3 has been deposited with the American Type Culture Collection under ATCC Accession Number 68503.
  • the HIV-1 gpl20 encoding region was ligated into expression plasmid pANTIGEN-2.
  • pANTIGEN-2 was linearized by Sail digestion, the overhang removed by ung bean nuclease digestion, and dephosphorylated with calf intestinal phosphatase.
  • the gpl20 encoding region was then liberated from plasmid pBHIO (Hahn et al . , 1984) by Xhol-Sall digestion and the 3.1 Kb fragment purified.
  • the env coding region then purified and further fragmented by a combination of mechanical shearing (rapid and repeated pipetting) and Sau3A partial digestion.
  • the resultant fragments were then split into four tubes for serial end repair to restore all possible reading frames.
  • dCTP and the Klenow fragment of DNA polymerase I was added to complement the first base of a Sau3A overhang (GATC) .
  • GATC Sau3A overhang
  • the remaining overhang was removed by mung bean nuclease.
  • dCTP and dTTP were incorporated as just described before mung bean nuclease treatment.
  • three and four base repair reactions were performed in tubes 3 and 4 respectively.
  • each tube was heated to 55°C to inactivate the polymerase, and the DNA fragments recovered by precipitation in ethanol. The fragments were then dissolved in water and combined. Thus, the combined tubes contained all of the possible reading frames in both orientations of the DNA fragments.
  • env encoding fragments were then ligated into the blunt-ended Sail site of pANTIGEN-2. Ligation mixtures were precipitated in ethanol, rehydrated and used to transform competent HB101 (pGPI-2) . Transformants were grown on L plates containing carbenicillin (Cb) , kanamycin (Km) , and 5-bromo-4-chloro- 3-indoylphosphate (XP) at 30°C until colonies reached approximately 1 mm in diameter. The plates were then incubated at 42°C for 1 hr to induce the T7 RNA polymerase encoded by pGPl-2. Under these conditions colonies expressing alkaline phosphatase (AP) fusion proteins turned bright blue due the cleavage of XP by AP. Blue colonies were isolated and further characterized.
  • Cb carbenicillin
  • Km kanamycin
  • XP 5-bromo-4-chloro- 3-indoylphosphate
  • AP + clones Five ml cultures of AP + clones were grown in Luria broth (LB) containing Cb and Km at 30°C. After overnight growth, 0.2 ml of each culture was transferred to sterile 13 x 100 mm tubes containing 5 ml M9 medium and centrifuged at 5,000 x g for 10 min. The bacterial pellets were resuspended in 1 ml M9 supplemented with 0.1% 18 amino acids (minus cysteine and methionine) and incubated with vigorous shaking at 30°C for 60 min. The temperature was then shifted to 42°C for 15 min before the addition of rifampicin (Rf) at a final concentration of 200 ⁇ g/ml.
  • Rf rifampicin
  • DNA sequencing reactions were performed on plasmid DNA template using Sequenase (U.S. Biochemical Corp.,
  • Legionella pneumophila chromosomal DNA was used as a source of prokaryotic DNA.
  • Purified chromosomal DNA was sheared by sonication, fractionated by agarose electrophoresis, and the fragments ranging in size between 0.5-2 Kb was gel purified. The fragment ends were flushed by treatment with the Klenow fragment of DNA polymerase I and 4 dNTPs before ligation into Smal digested and dephosphorylated pANTIGEN-3.
  • Ligation mixtures were precipitated in ethanol, rehydrated in water and used to transform competent HB101 (pGPl-2) . Transformants were grown on L (Cb, Km, XPO plates at 30°C until colonies reached approximately 1 mm in diameter. The temperature was then shifted to 42°C for 1 hr to induce expression of T7 RNA polymerase encoded by pGPl-2. Colonies expressing fusion proteins, identified as AP + blue colonies, were collected for further analysis.
  • DNA sequencing reactions were performed on plasmid DNA template using Sequenase and premixed dideoxy- and deoxynu ⁇ leotide triphosphates. Primers to initiate DNA synthesis from the 5'-terminal region of the phoA gene were used to characterize the fusion joint at the 3'-end of the inserted DNA segment.
  • ELISA Pro-Bind plates (Falcon 3915, Becton- Dickinson, Lincoln Park, NJ) were coated with 25 ⁇ g/ml goat anti-human Fc c antibody (Jackson Immuno-Research Laboratories, WestGrove, PA) (diluted in PBS) at 4°C overnight.
  • the wells were washed 3 times with PBS containing 0.05% Tween-20 (PBST) before the addition of test sear (diluted in PBS0. Following incubation at 37°C for 2 hr, the wells were washed 3 times with PBST to remove unbound antibody. Non-specific binding sites were blocked by the addition of PBS-3% gelatin (1 hr, room temperature) .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention se rapporte à des vecteurs de clonage obtenus par ingénierie biochimique et conçus pour générer une grande quantité de protéines de fusion à identification immédiate, dérivées d'un ADN étranger ou de parties dudit ADN. Les vecteurs acceptent un ADN eucaryote ou procaryote, un ADN chromosomique, un ADNc ou un ADN provenant d'un gène cloné précédemment. La conception générale du vecteur comprend un promoteur adaptatif, une séquence de peptides codant un signal, un site de clonage multiple et un gène de signalisation. Structuré de cette façon, le gène de signalisation codé par le vecteur est silencieux; cependant, après l'introduction de l'ADN, une protéine hybride peut s'exprimer, ce qui permet une conversion phénotypique détectable immédiatement. L'invention se rapporte également à un procédé de capture d'anticorps servant à détecter des antigènes spécifiques préparés en tant que protéines de fusion exprimées à partir d'hôtes bactériens transformés par lesdits vecteurs de clonage.
PCT/US1992/004866 1991-06-13 1992-06-10 Expression et systeme de detection de conjugues antigene-enzyme WO1992022657A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71416491A 1991-06-13 1991-06-13
US714,164 1991-06-13

Publications (1)

Publication Number Publication Date
WO1992022657A1 true WO1992022657A1 (fr) 1992-12-23

Family

ID=24868980

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/004866 WO1992022657A1 (fr) 1991-06-13 1992-06-10 Expression et systeme de detection de conjugues antigene-enzyme

Country Status (2)

Country Link
AU (1) AU2236592A (fr)
WO (1) WO1992022657A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001096554A1 (fr) * 2000-06-15 2001-12-20 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag Vecteur et procede d'expression et de selection de sequences de peptides aleatoires
EP1047453A4 (fr) * 1998-01-21 2002-08-28 Smithkline Beecham Corp Procede servant a determiner le caractere essentiel d'un gene chez un pathogene
WO2006071970A3 (fr) * 2004-12-23 2007-04-12 Univ Georgetown Procedes de detection d'analytes dans un echantillon
WO2008089132A3 (fr) * 2007-01-12 2008-11-13 Cornell Res Foundation Inc Sélection génétique pour le repliement des protéines et la solubilité dans le périplasme bactérien
US8987173B2 (en) 2005-08-01 2015-03-24 Cornell Research Foundation, Inc. Compositions and methods for monitoring and altering protein folding and solubility
US9150850B2 (en) 2005-08-22 2015-10-06 Cornell Research Foundation, Inc. Compositions and methods for analyzing protein interactions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983004262A1 (fr) * 1982-05-25 1983-12-08 Brandeis University Procede de production de fragments de proteine
EP0098118A1 (fr) * 1982-06-25 1984-01-11 Litton Bionetics, Incorporated Vecteurs contenant des cadres de lecture ouverts
WO1984004395A1 (fr) * 1983-04-23 1984-11-08 Battelle Institut E V Procede de determination de complexes antigene/anticorps

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1983004262A1 (fr) * 1982-05-25 1983-12-08 Brandeis University Procede de production de fragments de proteine
EP0098118A1 (fr) * 1982-06-25 1984-01-11 Litton Bionetics, Incorporated Vecteurs contenant des cadres de lecture ouverts
WO1984004395A1 (fr) * 1983-04-23 1984-11-08 Battelle Institut E V Procede de determination de complexes antigene/anticorps

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GENE vol. 33, no. 1, 1985, ELSEVIER PUBL., AMSTERDAM, NL; pages 103 - 119 C. YANISCH-PERRON ET AL. 'Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors' *
INFECTION AND IMMUNITY vol. 58, no. 11, November 1990, AM. SOC. MICROBIOL.,BALTIMORE,US; pages 3645 - 3652 R.G. URBAN ET AL. 'Construction of a bifunctional Escherichia coli heat-stable enterotoxin (STb)-alkaline phosphatase fusion protein' *
PROC. NATL. ACAD. SCI. vol. 85, March 1988, NATL. ACAD SCI., WASHINGTON, DC, US; pages 1932 - 1936 T.J. PALKER ET AL. 'Type specific neutralization of the human immnuodefiency virus with antibodies to the env-encoded sysnthetic peptides' *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1047453A4 (fr) * 1998-01-21 2002-08-28 Smithkline Beecham Corp Procede servant a determiner le caractere essentiel d'un gene chez un pathogene
WO2001096554A1 (fr) * 2000-06-15 2001-12-20 Intercell Biomedizinische Forschungs- Und Entwicklungs Ag Vecteur et procede d'expression et de selection de sequences de peptides aleatoires
WO2006071970A3 (fr) * 2004-12-23 2007-04-12 Univ Georgetown Procedes de detection d'analytes dans un echantillon
US8987173B2 (en) 2005-08-01 2015-03-24 Cornell Research Foundation, Inc. Compositions and methods for monitoring and altering protein folding and solubility
US9150850B2 (en) 2005-08-22 2015-10-06 Cornell Research Foundation, Inc. Compositions and methods for analyzing protein interactions
WO2008089132A3 (fr) * 2007-01-12 2008-11-13 Cornell Res Foundation Inc Sélection génétique pour le repliement des protéines et la solubilité dans le périplasme bactérien
US8722584B2 (en) 2007-01-12 2014-05-13 Cornell University Genetic selection for protein folding and solubility in the bacterial periplasm

Also Published As

Publication number Publication date
AU2236592A (en) 1993-01-12

Similar Documents

Publication Publication Date Title
US4663290A (en) Production of reverse transcriptase
EP0494955B1 (fr) Synthese et isolation sans cellule de nouveaux genes et de nouveaux polypeptides
KR101268939B1 (ko) 융합 폴리펩티드의 공번역 전좌를 사용한 파아지디스플레이
US5981177A (en) Protein fusion method and constructs
JPH0776596A (ja) ペプチド、融合ペプチド、発現ベクター及び組換えタンパク質の製造方法
CA2122135C (fr) Streptavidine recombinante
JPH0773504B2 (ja) 選択成熟蛋白質またはポリペプチドを細菌宿主内で合成する方法
US4503142A (en) Open reading frame vectors
HU193504B (en) Process for preparing and applying recombinated plasmids containing basic phosphatase gens
CA2136178A1 (fr) Production de straptavidine a partir bacillus subtilis
EP1220933B3 (fr) Purification de proteines recombinees fixees sur des epitopes multiples
US20090176281A1 (en) Modular vector systems
EP0850299B1 (fr) Presentation combinee ligand et recepteur
US4954618A (en) Cloned streptococcal genes encoding protein G and their use to construct recombinant microorganisms to produce protein G
US5362644A (en) Hybrid proteins between an extracytoplasmic enzyme and at least another protein, method for preparing them and also their applications
WO1992022657A1 (fr) Expression et systeme de detection de conjugues antigene-enzyme
US5082773A (en) Cloned streptococcal genes encoding protein G and their use to construct recombinant microorganisms to produce protein G
US5312901A (en) Cloned streptococcal genes encoding protein G and their use to construct recombinant microorganisms to produce protein G
Sprengel et al. Translationally coupled initiation of protein synthesis in Bacillus subtilis
Maclntyre et al. Requirement of the SecB chaperone for export of a non-secretory polypeptide in Escherichia coli
CA2753782C (fr) Presentation sur phage de proteines pix independante de la sequence du signal
CA2274986A1 (fr) Marquage d'epitope independant du cadre de lecture
US5229492A (en) Cloned streptococcal genes encoding protein G and their use to construct recombinant microorganisms to produce protein G
US7122346B2 (en) Process for the recombinant production of ribonucleoproteins
JPH06510901A (ja) 普遍性の部位特異的ヌクレアーゼ

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO PL RO RU SD SE

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU MC ML MR NL SE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载